PSMA Expression in the Hi-Myc Model; Extended Utility of a Representative Model of Prostate Adenocarcinoma for Biological Insight and as a Drug Discovery Tool
B. W. Simons, N. F. Turtle, D. Ulmert, D. Abou, D. L. Thorek
Abstract
Prostate specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII), is highly overexpressed in primary and metastatic prostate cancer (PCa). This has led to the development of radiopharmaceuticals for targeted imaging and therapy under current clinical evaluation. Despite this progress, the exact biological role of the protein in prostate cancer development and progression has not been fully elucidated. This is in part because the human PSMA and mouse PSMA (mPSMA) have different patterns of anatomical expression which confound study in the most widely utilized model organisms. Most notably, mPSMA is not expressed in the healthy murine prostate. Here, we reveal that mPSMA is highly upregulated in the prostate and prostate adenocarcinoma in the spontaneous Hi-Myc mouse model, a highly accurate and well characterized mouse model of prostate cancer development. Antibody detection and molecular imaging tools are used to confirm that mPSMA is expressed from early prostatic intraepithelial neoplasia (PIN) through adenocarcinoma.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- IL-1β/IL-6 signaling circuit in the tumor microenvironment drives prostate cancer development
Young Sun Lee, Jimmy L. Zhao, … Charles L. Sawyers·bioRxiv·Jul 31, 2026
- Prostate Specific Membrane Antigen expression in the vasculature of primary lung carcinomas associates with faster metastatic dissemination to brain
J. Tanjore Ramanathan, S. Lehtipuro, … P. Laakkonen·bioRxiv·Dec 8, 2019
- Pyruvate kinase M1 suppresses development and progression of prostate adenocarcinoma
S. M. Davidson, J. E. Heyman, … M. G. Vander Heiden·bioRxiv·May 9, 2021
- The expression of PKM1 and PKM2 in developing, benign, and cancerous prostatic tissues
- PSMA-specific CAR-engineered macrophages for therapy of prostate cancer
Yangli Xu, Duoli Xie, … Xiushan Yin·bioRxiv·Sep 7, 2024
- MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity
N. C. Whitlock, S. Y. Trostel, … A. G. Sowalsky·bioRxiv·Nov 20, 2019